Advances in the Staging and Phenotyping of Cardiogenic Shock: Part 1 of 2.
cardiac intensive care unit
cardiogenic shock
mortality
phenotypes
shock
Journal
JACC. Advances
ISSN: 2772-963X
Titre abrégé: JACC Adv
Pays: United States
ID NLM: 9918419284106676
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
03
04
2022
revised:
30
06
2022
accepted:
11
08
2022
medline:
28
10
2022
pubmed:
28
10
2022
entrez:
28
6
2024
Statut:
epublish
Résumé
Cardiogenic shock (CS) is a heterogeneous syndrome reflecting a broad spectrum of shock severity, diverse etiologies, variable cardiac function, different hemodynamic trajectories, and concomitant organ dysfunction. These factors influence the clinical presentation, management, response to therapy, and outcomes of CS patients, necessitating a tailored approach to care. To better understand the variability inherent to CS populations, recent algorithms for staging the severity of CS have been described and validated. This paper is part 1 of a 2-part state-of-the-art review. In this first article, we consider the context for clinical staging and stratification in CS with a focus on established severity staging systems for CS and their use for risk stratification and clinical care. We describe the use of staging for predicting outcomes in populations with or at risk for CS, including risk modifiers that provide more nuanced risk stratification, and highlight how these approaches may allow individualized care.
Identifiants
pubmed: 38939719
doi: 10.1016/j.jacadv.2022.100120
pii: S2772-963X(22)00170-3
pmc: PMC11198663
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100120Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
Mr Kennedy is supported by 10.13039/100000002NIH/10.13039/100000057NIGMS 2R35GM119519-06 and 10.13039/100000002NIH/10.13039/100000057NIGMS 1R21GM144851-01. Dr Baran is a current consultant for Livanova and Getinge; has been a prior consultant for Abiomed and Abbott; is currently on the steering committee of Procyrion and CareDx; and is a speaker (current) for Pfizer. Dr Kapur has received speaker honoraria/consultant fees from Abbott, Abiomed, Boston Scientific, Edwards, Getinge, LivaNova, and Zoll; and has received institutional research grants from Abbott, Abiomed, Boston Scientific, Getinge, and LivaNova. Dr Mebazza has received personal fees from Orion, Roche, Adrenomed, and Fire 1; and grants and personal fees from 4TEEN4, Abbott, Roche, and Sphyngotec. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.